Volume 15 Supplement 3
Edited by Lee Simon (Guest Editor)
The supplement was proposed by the journal and developed by the journal in collaboration with the Guest Editor. The Guest Editor assisted the journal in preparing the outline for the project but did not have oversight of the peer review process. The Guest Editor serves as a clinical and regulatory consultant in drug development and has served as such consultant for companies which manufacture and market NSAIDS including Pfizer, Pozen, Horizon Pharma, Logical Therapeutics, Nuvo Research, Iroko Imprimis, JRX Pharma, Nuvon, Medarx, Asahi. The articles have been through the journal's standard peer review process. Publication of this supplement has been supported by Horizon Pharma Inc. Duexis (ibuprofen and famotidine) is a product marketed by the sponsor.
2017 Journal Metrics
62 days to first decision for reviewed manuscripts only
50 days to first decision for all manuscripts
136 days from submission to acceptance
27 days from acceptance to publication